VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”) is scheduled to present at the 16th Annual World Vaccine Congress Europe on Tuesday, November 10th, 2015 at 6:30 AM ET (12:30 PM CET). The event is being held at the Silken Puerta América in Madrid, Spain.

Adam Buckley, VBI’s Vice President of Business Development, will provide an overview of VBI’s eVLP Platform and new data supporting the company’s respiratory syncytial virus (“RSV”) and cytomegalovirus (“CMV”) vaccine programs during his presentation, Novel Vaccine Candidates through Natural Presentation of Antigens in Enveloped Virus-like Particles.

Download the Presentation >>

RSV Vaccine Program Update

VBI’s eVLP Platform enables the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the structure of enveloped viruses found in nature. VBI, with grant funding from the National Research Council-Industrial Research Assistance Program, plans to apply its eVLP Platform in the development of a novel RSV vaccine candidate.

New manufacturing characterization data demonstrates that VBI is capable of producing eVLPs that express both pre-fusion and post-fusion conformations of the RSV-F protein. A growing body of research suggests that the shape of target proteins in an RSV vaccine may influence the potency of a vaccine candidate; the presence of pre-fusion RSV-F protein may allow for the development of a vaccine candidate capable of eliciting a potent immune response.1,2

RSV remains a significant unmet medical need. Globally, RSV is responsible for 6.7% of deaths in infants one month to one year old, more than any other single pathogen except malaria.3

CMV Vaccine Program Update

VBI’s lead eVLP Platform candidate is a preventative CMV vaccine. VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials.

New data from preclinical rabbit studies indicates that VBI’s CMV vaccine candidate is capable of eliciting potent CMV neutralization, equivalent to or exceeding levels found in human samples from individuals previously exposed to CMV via natural infection. This data adds to a body of existing animal data that supports planned Phase I human studies.4 Additionally, VBI’s CMV vaccine candidate has proven to be safe and non-reactogenic in toxicology testing that has now been completed.

CMV can cause serious disease in newborns when a mother is infected during pregnancy. Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, some of them severe, including deafness, blindness, and mental retardation.5

Event Details

  • Event: World Vaccine Congress Europe
  • Date: Tuesday, November 10th, 2015
  • Time: 6:30 AM ET (12:30 PM CET)
  • Location: Silken Puerta América in Madrid, Spain
  • Event Website: http://bit.ly/wvc-europe-2015